company background image
ADCT

ADC Therapeutics NYSE:ADCT Stock Report

Last Price

US$4.82

Market Cap

US$385.3m

7D

-1.4%

1Y

-81.7%

Updated

01 Oct, 2022

Data

Company Financials +
ADCT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ADCT Stock Overview

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors.

ADC Therapeutics SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ADC Therapeutics
Historical stock prices
Current Share PriceUS$4.82
52 Week HighUS$32.00
52 Week LowUS$4.58
Beta1.11
1 Month Change-28.91%
3 Month Change-43.56%
1 Year Change-81.74%
3 Year Changen/a
5 Year Changen/a
Change since IPO-83.74%

Recent News & Updates

Sep 16

ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval

A committee of the European Medicines Agency (EMA) recommended the approval of ADC Therapeutics (NYSE:ADCT) and Swedish Orphan Biovitrum's (Sobi) Zynlonta (loncastuximab tesirine) in EU to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The positive opinion by the EMA's Committee for Medicinal Products for Human Use (CHMP) was backed by data from a phase 2 trial called LOTIS-2. Approval decision from the European Commission's (EC), which generally follows the opinion of the CHMP, is expected in Q4 2022, the companies said in a Sept. 16 press release. ADC has license agreements for Zynlonta with Sobi and Mitsubishi Tanabe Pharma for certain regions.

Sep 09

ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11

Morgan Stanley downgraded ADC Therapeutics (NYSE:ADCT) to Equal Weight from Overweight in a research note issued on Friday. The investment bank lowered its price target to $11 from $17 on the commercial-stage biotechnology firm ADC Therapeutics (ADCT), citing Zynlonta penetration concerns. Stock is down 6% to trade at $6.16 on Friday. Seeking Alpha Quant Rating system assigns a Sell rating to ADCT, which sets the stock analysis stand apart from Wall Street's Strong Buy.

Shareholder Returns

ADCTUS BiotechsUS Market
7D-1.4%0.4%-2.5%
1Y-81.7%-25.6%-23.2%

Return vs Industry: ADCT underperformed the US Biotechs industry which returned -25.6% over the past year.

Return vs Market: ADCT underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is ADCT's price volatile compared to industry and market?
ADCT volatility
ADCT Average Weekly Movement12.2%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: ADCT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ADCT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011312Ameet Mallikhttps://www.adctherapeutics.com

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors.

ADC Therapeutics SA Fundamentals Summary

How do ADC Therapeutics's earnings and revenue compare to its market cap?
ADCT fundamental statistics
Market CapUS$385.28m
Earnings (TTM)-US$186.96m
Revenue (TTM)US$93.95m

4.1x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADCT income statement (TTM)
RevenueUS$93.95m
Cost of RevenueUS$160.21m
Gross Profit-US$66.26m
Other ExpensesUS$120.70m
Earnings-US$186.96m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.34
Gross Margin-70.53%
Net Profit Margin-199.01%
Debt/Equity Ratio269.6%

How did ADCT perform over the long term?

See historical performance and comparison